Shares of Agenus Inc. (NASDAQ:AGEN) dropped 1.7% during trading on Monday . The stock traded as low as $4.70 and last traded at $4.71, with a volume of 1,500,675 shares. The stock had previously closed at $4.79.

AGEN has been the topic of several research analyst reports. Maxim Group reiterated a “buy” rating on shares of Agenus in a research note on Wednesday, June 22nd. HC Wainwright reiterated a “buy” rating on shares of Agenus in a research note on Saturday, April 30th. Finally, Zacks Investment Research upgraded shares of Agenus from a “sell” rating to a “hold” rating in a report on Tuesday, July 5th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $10.47.

The firm has a 50 day moving average price of $4.15 and a 200-day moving average price of $3.77. The firm’s market cap is $409.21 million.

Agenus (NASDAQ:AGEN) last announced its quarterly earnings data on Thursday, April 28th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by $0.14. Analysts anticipate that Agenus Inc. will post ($1.36) earnings per share for the current year.

In other Agenus news, CEO Garo H. Armen acquired 100,000 shares of the company’s stock in a transaction that occurred on Monday, May 9th. The stock was purchased at an average price of $3.18 per share, for a total transaction of $318,000.00. Following the completion of the acquisition, the chief executive officer now owns 1,346,026 shares of the company’s stock, valued at approximately $4,280,362.68. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website.

An institutional investor recently raised its position in Agenus stock. Wells Fargo & Company MN raised its position in shares of Agenus Inc. (NASDAQ:AGEN) by 177.2% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 332,554 shares of the company’s stock after buying an additional 212,599 shares during the period. Wells Fargo & Company MN owned about 0.39% of Agenus worth $1,510,000 as of its most recent SEC filing.

Agenus Inc (Agenus) is an immunotherapy company. The Company is engaged in discovering and developing treatments for patients with cancer and other diseases. Its approaches are driven by three platform technologies: Its antibody platform, including Retrocyte Display technology, which is designed to produce human monoclonal antibodies focused on advancing checkpoint modulators (CPMs); its heat shock protein (HSP)-based vaccines, and its saponin-based vaccine adjuvants, QS-21 Stimulon adjuvant (QS-21 Stimulon).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.